Vivesto
ISIN
SE0000722365
Ticker
VIVE
Sector
Sub-Industry
Country
Sweden
Year Founded
1988
ISIN
SE0000722365
Ticker
VIVE
Sector
Sub-Industry
Country
Sweden
Year Founded
1988
Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.
Worldwide
| Line item in (sek) | 01.05.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 863,542,000.00 | 594,308,000.00 | 355,876,000.00 |
| Noncurrent Assets | N/A | 447,462,000.00 | 457,813,000.00 | 205,558,000.00 |
| Property Plant And Equipment | N/A | 17,630,000.00 | 17,108,000.00 | 12,964,000.00 |
| Intangible Assets Under Development | N/A | 420,334,000.00 | 400,799,000.00 | 158,408,000.00 |
| Other Intangible Assets | N/A | 9,197,000.00 | 39,605,000.00 | 33,885,000.00 |
| Current Assets | N/A | 416,079,000.00 | 136,495,000.00 | 150,318,000.00 |
| Inventories | N/A | 51,496,000.00 | 9,897,000.00 | 0.00 |
| Current Trade Receivables | N/A | 1,489,000.00 | 10,101,000.00 | 1,259,000.00 |
| Other Current Receivables | N/A | 43,063,000.00 | 8,680,000.00 | 2,328,000.00 |
| Cash and cash equivalents | 201,018,000.00 | 40,128,000.00 | 7,912,000.00 | 9,467,000.00 |
| Current Investments | N/A | 247,277,000.00 | 89,357,000.00 | 133,046,000.00 |
| Equity And Liabilities | N/A | 863,542,000.00 | 594,308,000.00 | 355,876,000.00 |
| Equity | 819,389,000.00 | 680,197,000.00 | 549,713,000.00 | 325,424,000.00 |
| Issued Capital | N/A | 44,837,000.00 | 44,837,000.00 | 53,804,000.00 |
| Retained Earnings | N/A | -1,268,657,000.00 | -1,401,379,000.00 | -1,758,098,000.00 |
| Other Reserves | N/A | -743,000.00 | 427,000.00 | 390,000.00 |
| Additional Paidin Capital | N/A | 1,904,760,000.00 | 1,905,828,000.00 | 2,029,327,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 680,197,000.00 | 549,713,000.00 | 325,424,000.00 |
| Noncontrolling Interests | N/A | 0.00 | 0.00 | 0.00 |
| Liabilities | N/A | 183,345,000.00 | 44,595,000.00 | 30,452,000.00 |
| Noncurrent Liabilities | N/A | 6,545,000.00 | 5,141,000.00 | 5,181,000.00 |
| Current Liabilities | N/A | 176,800,000.00 | 39,454,000.00 | 25,272,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 10,678,000.00 | 13,590,000.00 | 7,000,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 17,270,000.00 | 12,956,000.00 |
| Other Current Payables | N/A | 4,660,000.00 | 3,307,000.00 | 2,329,000.00 |
| Line item in (sek) | 01.05.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 482,000.00 | 26,192,000.00 | 1,015,000.00 |
| Other Income | 2,489,000.00 | 42,481,000.00 | 3,962,000.00 |
| Changes In Inventories Of Finished Goods And Work In Progress | -21,672,000.00 | 42,258,000.00 | 10,246,000.00 |
| Other Work Performed By Entity And Capitalised | 0.00 | 0.00 | N/A |
| Raw Materials And Consumables Used | 4,062,000.00 | 1,864,000.00 | 1,425,000.00 |
| Employee Benefits Expense | 45,519,000.00 | 44,883,000.00 | 33,829,000.00 |
| Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 28,930,000.00 | 28,877,000.00 | 256,155,000.00 |
| Other Expense By Nature | 77,627,000.00 | 79,438,000.00 | 58,371,000.00 |
| Profit Loss From Operating Activities | -131,493,000.00 | -128,647,000.00 | -355,049,000.00 |
| Finance Income | 4,138,000.00 | 2,460,000.00 | 1,460,000.00 |
| Finance Costs | 12,915,000.00 | 6,534,000.00 | 3,130,000.00 |
| Profit Loss Before Tax | -140,270,000.00 | -132,722,000.00 | -356,719,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -140,270,000.00 | -132,722,000.00 | -356,719,000.00 |
| Profit Loss Attributable To Owners Of Parent | -140,270,000.00 | -132,722,000.00 | -356,719,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 | 0.00 |
| Line item in (sek) | 01.05.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -140,270,000.00 | -132,722,000.00 | -356,719,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -22,658,000.00 | 41,599,000.00 | 9,897,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | -6,563,000.00 | 57,462,000.00 | 12,682,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | -11,846,000.00 | 2,874,000.00 | -6,590,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | N/A | 8,680,000.00 | -138,566,000.00 | -5,958,000.00 |
| Other Adjustments For Noncash Items | N/A | 29,413,000.00 | 28,877,000.00 | 256,155,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 680,000.00 | 552,000.00 | 495,000.00 |
| Interest Received Classified As Operating Activities | N/A | 3,000.00 | 0.00 | N/A |
| Cash Flows From Used In Operating Activities | N/A | -136,575,000.00 | -145,565,000.00 | -80,517,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 4,366,000.00 | 1,113,000.00 | 277,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 0.00 | 33,236,000.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | -14,366,000.00 | 118,651,000.00 | -45,277,000.00 |
| Proceeds From Issuing Shares | N/A | N/A | 0.00 | 150,652,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 4,010,000.00 | 5,809,000.00 | 5,495,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -4,010,000.00 | -5,809,000.00 | 128,763,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -154,952,000.00 | -32,723,000.00 | 2,969,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -5,938,000.00 | 507,000.00 | -1,414,000.00 |
| Cash and cash equivalents | 201,018,000.00 | 40,128,000.00 | 7,912,000.00 | 9,467,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 19.08.2021 | Anders Härfstrand | Other | Buy | SEK 53,132.58 |
| 16.07.2021 | Peter Zonabend | Other | Buy | SEK 302,623.60 |
| 14.07.2021 | Fredrik Järrsten | Other | Buy | SEK 58,200.00 |
| 13.07.2021 | Francois-Regis Martelet | Other | Buy | SEK 121,370.00 |
| 08.07.2021 | Birgit Agneta Stattin Norinder | Other | Buy | SEK 104,480.00 |
| 06.07.2021 | Anders Härfstrand | Other | Buy | SEK 285,653.00 |
| 13.10.2020 | Francois-Regis Martelet | Other | Buy | SEK 85,000.00 |
| 12.10.2020 | Anders Härfstrand | Other | Buy | SEK 130,800.00 |
| 18.06.2020 | Sven Rohmann | Other | Sell | SEK 620,638.00 |
| 18.06.2020 | Sven Rohmann | Other | Sell | SEK 504,702.80 |
SE0000722365
5493003TZPR4B7QO9L49
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.